Patents by Inventor Luigi Lenaz

Luigi Lenaz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF PRIMARY AND METASTATIC CARCINOMA
    Publication number: 20180280468
    Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 4, 2018
    Inventors: Anthony W. Tolcher, Luigi Lenaz
  • Treatment of primary and metastatic carcinoma
    Patent number: 10022421
    Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: July 17, 2018
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Anthony W. Tolcher, Luigi Lenaz
  • TREATMENT OF PRIMARY AND METASTATIC CARCINOMA
    Publication number: 20160287660
    Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
    Type: Application
    Filed: March 4, 2016
    Publication date: October 6, 2016
    Inventors: Anthony W. Tolcher, Luigi Lenaz
  • Treatment of primary and metastatic carcinoma
    Patent number: 9308235
    Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: April 12, 2016
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Anthony W. Tolcher, Luigi Lenaz
  • Bladder cancer treatment and methods
    Patent number: 9295666
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: March 29, 2016
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Sensitization of tumor cells to radiation therapy through administration of endothelin agonists
    Patent number: 8957014
    Abstract: Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: February 17, 2015
    Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinoise
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • BLADDER CANCER TREATMENT AND METHODS
    Publication number: 20140288143
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, bladder cancer treatments include the intravesical administration of apaziquone immediately following transurethral resection. Also disclosed are therapeutic compositions comprising an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Application
    Filed: February 5, 2014
    Publication date: September 25, 2014
    Applicant: Spectrum Pharmaceuticals, Inc.
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Luigi Lenaz, Shanta Chawla, Mario Beer
  • Methods, compositions and articles of manufacture for contributing to the treatment of cancers
    Patent number: 8729023
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: May 20, 2014
    Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • BLADDER CANCER TREATMENT AND METHODS
    Publication number: 20140073680
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 13, 2014
    Applicant: Spectrum Pharmaceuticals, Inc.
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Methods and compositions for contributing to the treatment of cancers
    Patent number: 8642026
    Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: February 4, 2014
    Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • TREATMENT OF PRIMARY AND METASTATIC CARCINOMA
    Publication number: 20130338079
    Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
    Type: Application
    Filed: May 9, 2013
    Publication date: December 19, 2013
    Applicant: Spectrum Pharmaceuticals, Inc.
    Inventors: Anthony W. Tolcher, Luigi Lenaz
  • Bladder cancer treatment and methods
    Patent number: 8563592
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: October 22, 2013
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Methods, compositions and articles of manufacture for contributing to the treatment of cancers
    Patent number: 8440620
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: May 14, 2013
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
    Patent number: 8394757
    Abstract: Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: March 12, 2013
    Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Methods and compositions for contributing to the treatment of cancers
    Patent number: 8349802
    Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: January 8, 2013
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Methods, Compositions and Articles of Manufacture for Contributing to the Treatment of Cancers
    Publication number: 20110315575
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
    Type: Application
    Filed: August 29, 2011
    Publication date: December 29, 2011
    Applicants: The Board of Trustees of the University of Illinois, Spectrum Pharmaceuticals, Inc.
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Methods and Compositions for Contributing to the Treatment of Cancers
    Publication number: 20110311481
    Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
    Type: Application
    Filed: August 29, 2011
    Publication date: December 22, 2011
    Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • BLADDER CANCER TREATMENT AND METHODS
    Publication number: 20110288472
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, bladder cancer treatments include the intravesical administration of apaziquone immediately following transurethral resection. Also disclosed are therapeutic compositions comprising an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Application
    Filed: April 8, 2011
    Publication date: November 24, 2011
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Luigi Lenaz, Shanta Chawla, Mario Beer
  • BLADDER CANCER TREATMENT AND METHODS
    Publication number: 20110288143
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Application
    Filed: April 8, 2011
    Publication date: November 24, 2011
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Methods, compositions and articles of manufacture for contributing to the treatment of cancers
    Patent number: 8030278
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: October 4, 2011
    Assignees: Spectrum Pharmaceuticals, Inc., Board of Trustees University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz